Crizonix

Crizonix (Crizotinib) is a kinase inhibitor used in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive. Crizotinib is the first FDA-approved biomarker-driven therapy for both ALK positive and ROS1-positive metastatic NSCLC. It is the only FDA approved drug for ROS 1 positive NSCLC.

Crizonix comes in a pack of 28 capsules, each capsule containing 250mg of the active ingredient Crizotinib.

Follow the dosing instructions provided by your doctor including what dosage to take, how often to take Crizotinib, when to take Crizotinib and how long to take Crizotinib for.

Crizonix is indicated for the first-line treatment of adults with ALK-positive advanced NSCLC (non-small cell lung cancer) and for the treatment of adults with previously treated ALK-positive advanced NSCLC & ROS1 (+) NSCLC. Crizotinib is an ALK and ROS1 (c-ros oncogene 1, receptor tyrosine kinase) inhibitor.